Outcomes in critically ill patients with hematologic malignancies who received renal replacement therapy for acute kidney injury in an intensive care unit

Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit

“…These results are consistent with previous studies, which suggested that IMV is a strong predictor of mortality in patients with hematologic malignancies [5][6][7]11,12,19]. Other factors thought to be associated with high mortality when admitted to the ICU include old age, the presence of hemodynamic instability, neutropenia, number of failing organs, and the presence of graft-versushost disease after allogeneic HSCT [5,[7][8][9][10][11][12][14][15][16].…”

“…Our cohort showed relatively high mortality compared with previous studies [5][6][7][8][9][10][11][12]15], although age and overall APACHE II score were not significantly different. These results could be partially explained by the fact that the proportion of difficult-to-treat acute leukemia in our series was relatively high because lots of patients with poor prognostic factors (old age [20][21][22], relapsed [23], previously failed to treat, or no candidate for HSCT donors [24]) were transferred to our institution.…”

“…In some previous studies [5][6][7][8][9]11,12,16,19], the type of hematologic malignancy does not predict mortality. On the other hand, 2 reports [27,28] suggested an association between underlying AML and high mortality.…”

“…Therefore, we wanted to focus on factors, which could affect survival in ICU by receiving intensive care. Moreover, many previous studies also used ICU mortality as an end point [5][6][7][8][9].…”

“…Unfortunately, more intense cancer treatment has led to increasing numbers of therapyassociated complications, which may be life threatening and often necessitate transfer to an intensive care unit (ICU). Although favorable ICU survival rates have been reported in critically ill patients with cancer in recent decades [3,4], they remain very low in patients with hematologic malignancies, in whom ICU mortality rates are 30% to 82% and in-hospital and long-term mortality rates are even higher [5][6][7][8][9][10][11][12][13][14][15].…”